Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder
Autore:
Silver, AA; Shytle, RD; Sheehan, KH; Sheehan, DV; Ramos, A; Sanberg, PR;
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 9, volume: 40, anno: 2001,
pagine: 1103 - 1110
SICI:
0890-8567(200109)40:9<1103:MDPSOM>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSDERMAL NICOTINE; TIC SEVERITY; HALOPERIDOL; CHILDREN; ADOLESCENTS; PIMOZIDE; ADHD; RAT;
Keywords:
mecamylamine; nicotinic antagonist; Tourette's disorder; mood; children;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Silver, AA Univ S Florida, Dept Psychiat, Ctr Infant & Child Dev, 3515 E Fletcher Ave,MDC-14, Tampa, FL 33613 USA Univ S Florida 3515 E Fletcher Ave,MDC-14 Tampa FL USA 33613 SA
Citazione:
A.A. Silver et al., "Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder", J AM A CHIL, 40(9), 2001, pp. 1103-1110

Abstract

Objective: The safety and efficacy of mecamylamine as a monotherapy in children and adolescents with Tourette's disorder (TD) was investigated in an 8-week multicenter, double-blind, placebo-controlled study. Method: Eligible subjects included subjects with TD, (DSM-IV), with a naturalistic mix of comorbid diagnoses, nonsmokers, aged 8 to 17 years, whose behavioral and emotional symptoms (according to parents) were more disturbing than tics. After a washout period of all psychotropic medication, subjects were randomly assigned to either mecamylamine (n = 29) or placebo (n = 32). Mecamylamine doses ranged from 2.5 to 7.5 mg/day. Primary efficacy measures included theTourette's Disorder Scale-Clinician Rated (TODS-CR) and 21 point Clinical Global Improvement scale; secondary efficacy measures included the Yale Global Tic Severity Scale and a rage-attack scale (RAScal). Results: Of the 61subjects who were randomized, 50 (82%) completed at least 3 weeks on medication and 38 (62%) completed the full 8-week trial. Study withdrawals included 12/29 on mecamylamine and 11/32 on placebo. For the total sample, mecamylamine was no more effective than placebo on any of the outcome measures. However, an item analysis of the TODS-CR suggested that mecamylamine may have reduced sudden mood changes and depression in moderately to severely affected subjects. Except for a slight increase in heart rate during the 1st week in both the mecamylamine and the placebo groups, there where no significant mecamylamine-related changes in vital signs, electrocardiogram, complete blood cell count, or blood chemistry values. Conclusions: Mecamylamine, in doses up to 7.5 mg/day, is well tolerated in children and adolescents, but as a monotherapy it does not appear to be an effective treatment for tics or for the total spectrum of symptoms associated with TD. However, further studies should be conducted to investigate its possible therapeutic effects in subjects with comorbid mood disorders and as an adjunct to neuroleptic medication.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 18:33:44